



2024/11/28

產業類別	塑膠
投資建議	中立 
收盤價	目標價
NT\$ 16.15	NT\$

本次報告：法說會

交易資料

潛在報酬率 (%)	--
52 週還原收盤價區間 (NT\$)	14.77-21.70
市值 (NT\$百萬元)	6420
市值 (US\$百萬美元)	197
流通在外股數 (百萬股)	398.00
董監持股 (%)	39.37
外資持股 (%)	2.86
投信持股 (%)	0.00
融資使用率 (%)	5.58

財務資料

	2023
股東權益 (NT\$百萬元)	6,648
ROA (%)	-3.02
ROE (%)	-3.95
淨負債比率 (%)	25.23

公司簡介

台達化為 ABS、PS 生產廠商；台達化為生產 ABS、EPS、GPS、IPS 及玻璃棉等產品為主之廠家。公司目前 ABS/SAN 年產能 12 萬噸，GPS/IPS 年產能 10 萬噸，EPS 年產能 38 萬噸，玻璃棉產能 10,000 噸/年。2024 年前三季營收比重為 EPS 占 50%，ABS 占 25%，GPS 占 22%，玻璃棉占 3%。

主要客戶：
主要競爭對手：

葉家宏 bill.yeh@sinopac.com

台達化 (1309 TT)

獲利有望好轉，評價並未偏低


永豐觀點

台達化受惠 ABS、PS 利差持續改善，及開發海外新市場有成，2024 年毛利率表現逐季成長，台達化營運有望轉虧為盈，然考量 2025 年中國仍有大量 ABS 新增產能計畫開出，且台達化目前評價並未偏低，研究處給予台達化中立投資建議。

投資評價與建議


投資建議中立，主要係因：儘管台達化積極開發中國以外的海外市場，但因近年 ABS 新增產能巨大，加上 2025 年 SM 預計新增產能增幅小，原料成本壓力仍存，將壓抑 ABS 利差表現，而考量台達化目前 PBR 評價約位於 1X，參考過往評價下緣達 0.65X，目前評價並未明顯偏低，因此，研究處給予中立投資建議。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

營運現況與分析

台達化為 ABS、PS 生產廠商：台達化為生產 ABS、EPS、GPS、IPS 及玻璃棉等產品為主之廠家，公司目前 ABS/SAN 年產能 12 萬噸，GPS/IPS 年產能 10 萬噸，EPS 年產能 38 萬噸，玻璃棉產能 10,000 噸/年，2024 年前三季營收比重為 EPS 占 50%，ABS 占 25%，GPS 占 22%，玻璃棉占 3%。

表一：產品營收比重

產品	2020	2021	2022	2023
EPS	44%	42%	46%	46%
ABS	33%	36%	26%	25%
GPS	19%	19%	25%	25%
玻璃棉	3%	2%	3%	3%


資料來源：永豐投顧研究處整理，Nov. 2024

3Q24 稅後 EPS 為-0.25 元，低於預期：台達化 3Q24 營收 51.86 億元 (+4.9% QoQ, +30.3% YoY)，優於預期，主因中國實施家電舊換新政策，帶動 PS、ABS 產品需求好轉，毛利率 6.59% (+2.41 pts. QoQ, +4.5 pts. YoY)，符合預期，主要係因油價走勢弱勢，原料 SM 報價同步下行，然 ABS、PS 跌幅較小，利差表現好轉所致，營益率-1.31% (+0.66 pts. QoQ, +2.73 pts. YoY)，低於預期，主要係因海運費上漲，認列較高的費用金額所致，稅後淨利-9,897 萬元(虧損擴大 QoQ, 虧損擴大 YoY)，3Q24 稅後 EPS -0.25 元，低於預期。

4Q24 營運表現有望好轉：公司 10 月營收 14.83 億元，-11.6% MoM, +2.2% YoY，低於預期，主要係因 10 月生產受颱風影響，出貨量低於預期所致。展望 4Q24，油價走勢弱勢，原料 SM 報價持續下行，ABS、PS 報價同步下行，跌幅相對較小，有利利差表現好轉，ABS 虧損幅度預期將收斂，PS 則有望獲利轉虧為盈，ABS 預期將維持約 85%稼動率，PS 則維持全產全銷，基此，研究處預估 4Q24 營收 47.48 億元 (-8.4% QoQ, +16.9% YoY)，預估毛利率 7.56% (+0.97 pts. QoQ, +4.38 pts. YoY)，預估稅後淨利 4,224 萬元(轉虧為盈 QoQ, 轉虧為盈 YoY)，稅後 EPS 0.11 元。


評價並未明顯偏低，投資建議中立：展望 2024，受制於中國大量 ABS、PS 新增產能開出，台達化積極開發非中國市場，儘管市場需求依然疲弱，但台達化降低對中國市場的依賴，今年前三季 ABS 中國營收占比僅 16%，PS 中國營收占比僅 12%，並積極搶入印度市場，減少與中國低價貨源競爭，預期將帶動台達化 2024 年虧損幅度收斂，預估 2024 年營收 186.68 億元 (+22.8%YoY)，毛利率 5.03%，稅後淨利-1.98 億元(虧損縮小 YoY)，稅後 EPS -0.5 元。展望 2025，中國 ABS 新增產能規畫 220 萬噸(2024 年新增 120 萬噸)，EPS 新增產能規畫 120 萬噸(2024 年新增 140 萬噸)，GPS 新增產能規畫 40 萬噸(2022 年新增 40 萬噸)，上游原料 SM 新增產能規畫 100 萬噸(2024 年新增 195 萬噸)，觀察 PS 新增產能相對較少，利差表現有望持穩，ABS 中國新增產能持續龐大，供給壓力將持續增加，且上游 SM 新增產能同樣較少，將造成原料成本壓力持續存在，壓抑台達化獲利好轉幅度，基此，預估 2025 年營收 192.13 億元 (+2.9%YoY)，毛利率 6.57%，稅後淨利 5,201 萬元(轉虧為盈 YoY)，稅後 EPS 0.13 元，儘管台達化獲利展望有望好轉，但台達化目前 PBR 評價約位於 1X，參考過往評價下緣達 0.65X，目前評價並未明顯偏低，且後續隨著 ABS 新增產能投放，供需壓力仍存，因此，研究處給予中立投資建議。

圖一：PS 月均現貨報價及利差趨勢



資料來源：Platts、永豐投顧估算彙整，Nov. 2024

圖二：ABS 月均現貨報價及利差趨勢



資料來源：Platts、永豐投顧估算彙整，Nov. 2024

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3	24Q4F	2024F
營業收入	3,791	4,943	5,186	4,748	18,668
營業毛利	32	207	342	342	939
營業利益	-189	-97	-68	-68	-310
稅前淨利	-127	-47	-103	53	-224
稅後純益	-102	-39	-99	42	-198
稅後 EPS (元)	-0.26	-0.10	-0.25	0.11	-0.50
營收 QoQ 成長率	-6.68	30.40	4.91	-8.43	--
營收 YoY 成長率	6.03	37.78	30.28	16.92	22.78
毛利率	0.85	4.18	6.59	7.20	5.03
營益率	-4.99	-1.97	-1.31	-1.43	-1.66
稅後純益率	-2.68	-0.80	-1.91	0.88	-1.06

資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	20,771	18,084	15,205	18,668	19,213
%變動率	34.02	-12.94	-15.92	22.78	2.92
營業毛利	3,386	1,760	436	939	1,262
毛利率 (%)	16.30	9.73	2.86	5.03	6.57
營業淨利	2,247	225	-464	-310	19
稅前淨利	2,407	544	-346	-224	66
%變動率	-3	-77.39	--	--	--
稅後純益	1,850	412	-274	-198	52
%變動率	-3.64	-77.72	--	--	--
稅後 EPS * (元)	4.65	1.04	-0.69	-0.50	0.13
市調 EPS * (元)	4.59	1.13	-0.61	-0.80	--
PER (x)	3.47	15.53	--	--	124.23
PBR (x)	0.80	0.89	0.97	1.01	1.00
每股淨值 * (元)	20.23	18.12	16.72	16.04	16.17
每股股利 (元)	2.00	0.50	0.30	--	--
殖利率 (%)	6.82	2.33	1.85	--	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Nov. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.